"Inclusion in the FDA's TAP Program underscores the potential of Discure’s bioelectronic therapy, the Discure System, to reverse disc degeneration," said Yuval Mandelbaum, CEO of Discure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback